The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
High-Dose Therapy and Autologous Blood Stem-Cell Transplantation Compared With Conventional Treatment in Myeloma Patients Aged 55 to 65 Years: Long-Term Results of a Randomized Control Trial From the Group Myelome-Autogreffe
Open accessAbstract
Purpose: To study the impact of high-dose therapy (HDT) with autologous stem-cell support in patients with symptomatic multiple myeloma (MM) between the ages of 55 and 65 years. Patients and Methods: One hundred ninety patients between 55 and 65 years old who had newly diagnosed stage II or III MM were randomly assigned to receive either conventional chemotherapy (CCT; ie, monthly courses of a regimen of vincristine, melphalan, cyclophosphamide, and prednisone) or HDT and autologous blood stem-cell transplantation (using either melphalan alone 200 mg/m 2 intravenous [IV] or melphalan 140 mg/m 2 IV plus busulfan 16 mg/kg orally as pretransplantation cytoreduction). Results: Within a median follow-up of 120 months, median event-free survival (EFS) times were 25 and 19 months in the HDT and CCT groups, respectively. Median overall survival (OS) time was 47.8 months in the HDT group compared with 47.6 months in the CCT group. A trend to better EFS (P = .07) was observed in favor of HDT, whereas OS curves were not statistically different (P = .91). The period of time without symptoms, treatment, and treatment toxicity (TwiSTT) was significantly longer for the HDT patients than for the CCT patients (P = .03). Conclusion: With a median follow-up time of approximately 10 years, this randomized trial confirmed a benefit of HDT in terms of EFS and TwiSTT but did not provide evidence for superiority of HDT over CCT in OS of patients aged 55 to 65 years with symptomatic newly diagnosed MM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Staging System for Multiple Myeloma
Greipp, P. R., Miguel, J. S., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J. A., Avet-Loiseau, H., Kyle, R. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.242 · Cited by 2,974
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Ttal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma
Bergsagel, P. L., Kuehl, W. M., Zhan, F., Sawyer, J., Barlogie, B., & Shaughnessy, J. (2005) · Blood · doi:10.1182/blood-2005-01-0034 · Cited by 698
Testing for Qualitative Interactions between Treatment Effects and Patient Subsets
Gail, M., & Simon, R. (1985) · Biometrics · doi:10.2307/2530862 · Cited by 651
The Design and Analysis of Sequential Clinical Trials.
Harrington, D., & Whitehead, J. (1985) · Journal of the American Statistical Association · doi:10.2307/2288093 · Cited by 634
Thalidomide Alone or With Dexamethasone for Previously Untreated Multiple Myeloma
Weber, D., Rankin, K., Gavino, M., Delasalle, K., & Alexanian, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.139 · Cited by 566
Fermand, J.-P., Ravaud, P., Chevret, S., Divine, M., Leblond, V., Belanger, C., Macro, M., Pertuiset, E., Dreyfus, F., Mariette, X., et al. (1998) · Blood · doi:10.1182/blood.v92.9.3131 · Cited by 542
Self-citation
Cited by
Palumbo, A., & Anderson, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,326
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2008) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,240
DiPersio, J. F., Stadtmauer, E. A., Nademanee, A., Micallef, I. N. M., Stiff, P. J., Kaufman, J. L., Maziarz, R. T., Hosing, C., Früehauf, S., Horwitz, M., et al. (2009) · Blood · doi:10.1182/blood-2008-08-174946 · Cited by 789
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma
Attal, M., Harousseau, J.-L., Leyvraz, S., Doyen, C., Hulin, C., Benboubker, L., Agha, I. Y., Bourhis, J.-H., Garderet, L., Pegourie, B., et al. (2006) · Blood · doi:10.1182/blood-2006-05-022962 · Cited by 667
Kumar, S. K., Mikhael, J. R., Buadi, F. K., Dingli, D., Dispenzieri, A., Fonseca, R., Gertz, M. A., Greipp, P. R., Hayman, S. R., Kyle, R. A., et al. (2009) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0603 · Cited by 628
Mikhael, J. R., Dingli, D., Roy, V., Reeder, C. B., Buadi, F. K., Hayman, S. R., Dispenzieri, A., Fonseca, R., Sher, T., Kyle, R. A., et al. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.01.019 · Cited by 500
Giralt, S., Costa, L., Schriber, J., DiPersio, J., Maziarz, R., McCarty, J., Shaughnessy, P., Snyder, E., Bensinger, W., Copelan, E., et al. (2014) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2013.10.013 · Cited by 407
Cavo, M., Tosi, P., Zamagni, E., Cellini, C., Tacchetti, P., Patriarca, F., Di Raimondo, F., Volpe, E., Ronconi, S., Cangini, D., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2509 · Cited by 370
Multiple myeloma current treatment algorithms
Rajkumar, S. V., & Kumar, S. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00359-2 · Cited by 355
Kumar, S., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Gastineau, D. A., Litzow, M. R., Fonseca, R., Roy, V, Rajkumar, S. V., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404801 · Cited by 351
Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline
Mikhael, J., Ismaila, N., Cheung, M. C., Costello, C., Dhodapkar, M. V., Kumar, S., Lacy, M., Lipe, B., Little, R. F., Nikonova, A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02096 · Cited by 331
Kristinsson, S. Y., Landgren, O., Dickman, P. W., Derolf, Å. R., & Björkholm, M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.0100 · Cited by 319
Cavo, M., Rajkumar, S. V., Palumbo, A., Moreau, P., Orlowski, R., Bladé, J., Sezer, O., Ludwig, H., Dimopoulos, M. A., Attal, M., et al. (2011) · Blood · doi:10.1182/blood-2011-02-297325 · Cited by 314
van de Velde, H. J. K., Liu, X., Chen, G., Cakana, A., Deraedt, W., & Bayssas, M. (2007) · Haematologica · doi:10.3324/haematol.11534 · Cited by 283
Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
Kumar, S. K., Callander, N. S., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., Costello, C., Faiman, M., Fung, H. C., Gasparetto, C., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0023 · Cited by 279
Lahuerta, J. J., Mateos, M. V., Martínez-López, J., Rosiñol, L., Sureda, A., de la Rubia, J., García-Laraña, J., Martínez-Martínez, R., Hernández-García, M. T., Carrera, D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.9721 · Cited by 279
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology
Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L., Baljevic, M., Campagnaro, E., Castillo, J. J., Chandler, J. C., Costello, C., Efebera, Y., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0057 · Cited by 277
How I treat multiple myeloma in younger patients
Stewart, A. K., Richardson, P. G., & San-Miguel, J. F. (2009) · Blood · doi:10.1182/blood-2009-07-204651 · Cited by 133
Ling, S. C. W., Lau, E. K. K., Al-Shabeeb, A., Nikolic, A., Catalano, A., Iland, H., Horvath, N., Ho, P. J., Harrison, S., Fleming, S., et al. (2012) · Haematologica · doi:10.3324/haematol.2011.043331 · Cited by 130
“The median survival time is 4 to 5 years.(2-4) The relapse rate is high and relapsed myeloma is particularly resistant to conventional chemotherapy.”
Background
Metadata
- Authors
- Fermand, J.-P., Katsahian, S., Divine, M., Leblond, V., Dreyfus, F., Macro, M., Arnulf, B., Royer, B., Mariette, X., Pertuiset, E., Belanger, C., Janvier, M., Chevret, S., Brouet, J. C., & Ravaud, P.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-12-20
- Volume
- 23
- Issue
- 36
- Pages
- 9227-9233
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2107057207
- Cited by
- 399
- References
- 30
- FWCI
- 15.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.